Core Viewpoint - The National Healthcare Security Administration has issued a notice regarding the name changes of certain traditional Chinese medicine (TCM) decoction pieces in the 2025 edition of the Chinese Pharmacopoeia, ensuring that these changes do not affect the payment types for the respective decoction pieces under the basic medical insurance drug catalog [1]. Group 1: Name Changes of Funded Decoction Pieces - The notice includes a list of TCM decoction pieces whose names have changed in the 2025 edition of the Chinese Pharmacopoeia, which are still eligible for funding [2]. - Examples of name changes include: - Bai Jie Zi to Jie Zi - Chen Pi to Chen Pi (excluding Guang Chen Pi) - Dang Shen Pian to Dang Shen - Di Huang to Sheng Di Huang - Gan Cao Pian to Gan Cao [2]. Group 2: Name Changes of Non-Funded Decoction Pieces - The notice also outlines the name changes for TCM decoction pieces that are not eligible for funding under the new pharmacopoeia [3].

Core Insights - The new basic medical insurance drug list has been officially implemented since January 1, 2026, with many insured individuals already purchasing newly added drugs from medical institutions [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the basic medical insurance drug list, with over half of these drugs already recorded in sales at medical institutions [1] - The drug Tirzepatide injection, used for treating adult type 2 diabetes, has been sold in 1,433 medical institutions [1] - The long-acting lipid-lowering drug Icosapent ethyl injection, known for its "half-yearly injection" regimen, has been recorded in sales at 400 medical institutions [1] Group 2: Access and Information - Insured individuals can check the availability of insured drugs at medical institutions through the "National Medical Insurance Negotiated Drug Supply Institution List" on the National Medical Insurance Service Platform [1]